BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.60 Consensus Target Price from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $15.60.

A number of brokerages have issued reports on BCRX. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. Xponance Inc. raised its position in shares of BioCryst Pharmaceuticals by 13.1% during the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 1,505 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of BioCryst Pharmaceuticals by 19.4% in the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 2,644 shares during the period. Creative Planning lifted its stake in shares of BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after buying an additional 2,734 shares during the period. Finally, SkyView Investment Advisors LLC grew its position in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after buying an additional 3,000 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 1.7 %

BioCryst Pharmaceuticals stock opened at $7.70 on Friday. The company has a market capitalization of $1.59 billion, a P/E ratio of -12.62 and a beta of 1.76. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The firm’s fifty day simple moving average is $7.61 and its 200-day simple moving average is $7.52.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.19) EPS. On average, equities research analysts predict that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.